These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23016758)

  • 21. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
    Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
    Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Future trends in the treatment of serious Gram-positive infections.
    Metzger R; Bonatti H; Sawyer R
    Drugs Today (Barc); 2009 Jan; 45(1):33-45. PubMed ID: 19271030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria.
    Tang SS; Apisarnthanarak A; Hsu LY
    Adv Drug Deliv Rev; 2014 Nov; 78():3-13. PubMed ID: 25134490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antibacterial drug resistance in Latin America: consequences for infectious disease control].
    Casellas JM
    Rev Panam Salud Publica; 2011 Dec; 30(6):519-28. PubMed ID: 22358396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daptomycin - a novel antibiotic against Gram-positive pathogens.
    LaPlante KL; Rybak MJ
    Expert Opin Pharmacother; 2004 Nov; 5(11):2321-31. PubMed ID: 15500379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidrug-Resistant Enterococcal Infections: New Compounds, Novel Antimicrobial Therapies?
    van Harten RM; Willems RJL; Martin NI; Hendrickx APA
    Trends Microbiol; 2017 Jun; 25(6):467-479. PubMed ID: 28209400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vancomycin resistance: occurrence, mechanisms and strategies to combat it.
    Boneca IG; Chiosis G
    Expert Opin Ther Targets; 2003 Jun; 7(3):311-28. PubMed ID: 12783569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic resistance among clinically important gram-positive bacteria in the UK.
    Johnson AP
    J Hosp Infect; 1998 Sep; 40(1):17-26. PubMed ID: 9777517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview of resistant gram-positive pathogens in the surgical patient.
    Rapp RP
    Surg Infect (Larchmt); 2000; 1(1):39-47. PubMed ID: 12594908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Gram-positive bacterial infections resistant to antibiotic treatment].
    Utili R
    Ann Ital Med Int; 2001; 16(4):205-19. PubMed ID: 11799629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus.
    Cunha BA
    Med Clin North Am; 2006 Nov; 90(6):1165-82. PubMed ID: 17116442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches.
    Karaman R; Jubeh B; Breijyeh Z
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32586045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The possibility of drug design of quinolones effective for multiresistant gram-positive pathogens].
    Hayakawa I
    Nihon Rinsho; 1997 May; 55(5):1266-71. PubMed ID: 9155185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus.
    Shetty N; Wilson AP
    J Antimicrob Chemother; 2000 Oct; 46(4):633-8. PubMed ID: 11020265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010).
    Zhao C; Sun H; Wang H; Liu Y; Hu B; Yu Y; Sun Z; Chu Y; Cao B; Liao K; Lei J; Hu Z; Zhang L; Zhang X; Xu Y; Wang Z; Chen M
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):174-81. PubMed ID: 22521693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
    Jones RN; Low DE; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.